Google+ Facebook Twitter Twitter

CJD treatment trialled for first time

In a world first, doctors have been given permission to give a British man with CJD a pioneering treatment.

CJD is a rare but lethal brain disease for which there is no known cure, but the Court of Protection has given permission for the trial use on a human for the first time.

Scientists say lab testing of the man-made antibody has been encouraging, but they admit they do not know how their patient will respond.

The treatment is called PRN100 and aims to prevent abnormal prions from being able to attach themselves to healthy proteins, meaning that they cannot grow and cause devastation throughout the brain.

University College London Hospitals NHS Foundation Trust (UCLH) is set to use it in a patient for the first time after a judge confirmed that it was lawful.

Professor John Collinge, Director of the Medical Research Council Prion Unit at UCLH, who led the development of the treatment, said: “As this is the first time this treatment has been used in humans we cannot predict what the outcome will be, but laboratory testing has shown the potential to treat prion infection.”

Image credit | iStock

Related Articles

Discovering the double helix

A look back in time to the history of the discovery of DNA and its structure – work which would change medicine and science forever.

January: news in numbers

A breakdown of science news this month, in numbers.

Genetic changes associated with physical activity

The time we spend sitting, sleeping and moving is determined in part by our genes, University of Oxford researchers have shown.

Cancer Research Shutterstock

New genomics centre to open

Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the UK, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.